Blueprint Medicines (BPMC)
(Delayed Data from NSDQ)
$117.78 USD
-0.01 (-0.01%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $117.70 -0.08 (-0.07%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth B Momentum F VGM
Brokerage Reports
Blueprint Medicines Corporation [BPMC]
Reports for Purchase
Showing records 201 - 220 ( 518 total )
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
We See Minimal Disruption From Planned CEO Transition in ''22
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Blueprint?s Acquisition of Lengo Therapeutics Expands EGFR Pipeline
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
BPMC?s BLU-945 and BLUE-701 Enter China with Help from ZLAB
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Ayvakit Boasts Positive Launch in SM, While Gavreto May Have Hidden Tissue Agnostic Play
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
AYVAKIT Is (ASM)ilating Into the Patient Population
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department